Triastin in immunocorrection of women diagnosed with cancer breast controlled by iron-containing glands treatment efficacy indicator proteins

Abstract

The article shows that the treckresan BAA derivative triastin can be recocorrected for the immunocorrection of women of the menopause with a diagnosis of breast cancer under the control of determining the concentration of serum iron- containing indicator proteins (lactoferrin and ferritin). Results from a study of lactoferrin and ferritin levels in menopausal women diagnosed with breast cancer when triastine was prescribed are shown. It was found that in the main group, the use of triastine in addition to the main course of treatment caused an earlier (by 7-10 days) concentration of LF — from 401,22±27,58 до 4089,32±119,04 ng/ml and F — from 29,1±1,5 ng/ml до 494,30±13,6 ng/ml, compared with the control group — 1295,37±28,61 ng/ml и 288,59±15,5 ng/ml, respectively.